Serotonin Transporter (SLC6A4) Genotyping
The SLC6A4 (solute carrier family 6 (neurotransmitter transporter), member 4) gene encodes the neuronal serotonin transporter (SERT). The gene is located on chromosome 17q11.2. This is a protein present in presynaptic neurons. SERT is the molecular target of a large group of antidepressant drugs called selective serotonin re-uptake inhibitors or serotonin-specific reuptake inhibitor (SSRIs). Serotonin is a neurotransmitter that allows communication between neurons. SSRIs block the reabsorption of serotonin from the synaptic space into the pre-synaptic neuron terminal from which it originally arose. Changing the balance of serotonin seems to help neurons sending and receiving messages, and in turn help depression. Examples of SSRIs are fluoxetine (Prozac), fluvoxamine (Luvox), escitalopram oxalate (Lexapro), sertraline (Zoloft), citalopram (Celexa), and paroxetine (Paxil).
One important genetic variation that affects the efficacy of SSRIs is in the regulatory region of SLC6A4. The polymorphism is a 44-base pair (bp) insertion or deletion resulting in a Long A (LA)/Long G (LG) promoter variant or a Short A (S) promoter variant. The S or LG variant of SLC6A4 results in two-fold decreased expression and transport activity of SERT. The LA allele, in contrast, expresses normal levels of the SERT, while the LG and S alleles express lower levels. In comparison to LG or S variants, several published studies have shown an enhanced therapeutic response to SSRIs in LA homozygous patients (i.e., patients carrying two LA alleles of SLC6A4). LA homozygous patients express normal levels of the serotonin transporter and are, therefore, regarded as "SLC6A4 Normal Responders." When only one copy of the LA allele is presented, patients are designated as "SLC6A4 Intermediate Responders." These patients may have a decreased response or increased adverse reactions to SSRIs. Patients with S/S, S/LG, and LG/LG genotypes are designated as "SLC6A4 Poor Responders." They may have the least response and highest frequency of adverse effects when treated with SSRIs. Greater caution is recommended when SSRIs are given to individuals with the LG or S alleles. A repeat polymorphism in the promoter region of this gene has been associated with Sudden Infant Death Syndrome.
- Determining therapeutic strategy for SSRIs as antidepressant agents
- Monitor and manage SSRIs drug therapy
- Evaluating patients who have failed therapy with selective serotonin reuptake inhibitors (SSRIs)
- Evaluating patients with treatment-resistant depression
- If genotype SLC6A4 LA/LA is detected, this would be reported as normal responder
- Intermediate responders are LA/other alleles
- Poor responders include LG/LG, S/LG, S/S alleles
Short A (S) promoter variant, SS
Buccal swab and peripheral blood (EDTA) or saliva
Buccal swabs can be collected by rubbing the inside of the cheeks with a swab (similar to a Q-tip and generally 4 swabs). The swabs are transported to the laboratory in a liquid medium (see manufacturer guidelines for details) or dry swab.
Stability (Blood):
- Ambient: 5 days
- Refrigerated: 7 days
- Arch Gen Psychiatry. 2001 Jun;58(6):539-44. [PMID: 11386982]
- Am J Med Genet B Neurops Genet. 2009 Apr 5;150B(3):341-51. [PMID: 18618621]
- Biol Psychiatry. 2007 Mar 15;61(6):734-42. [PMID: 17123473]
- Mol Psych. 2007;12:247-257. [PMID: 17146470]
- Eur Neuropsychopharmacol. 2012 Apr;22(4):239-58. [PMID: 22137564]